Parkinson's Drug Shows Potential Against Brain Cancer
A new lab study suggests this common medication may affect the survival of glioblastoma cells in vitro.
Updated on Oct. 23, 2026 in Cancer
Researchers found that the Parkinson's medication rasagiline reduced the survival of human glioblastoma cells in a lab study published on October 23, 2026. This laboratory finding highlights a potential new area for brain cancer research.
Why it matters
Glioblastoma is an aggressive form of brain cancer, and scientists are exploring whether repurposing existing medications like rasagiline can offer new pathways for treatment. This discovery could eventually inform future research into how these drugs affect cancer cell survival.
This in vitro study evaluated the effect of rasagiline on human U87-MG and T98G glioblastoma cell lines over a 24-hour period. While the treatment reduced cell survival and modulated inflammatory pathways, these results are preliminary and have not been validated in vivo.
The details
The study indicates that rasagiline, an irreversible monoamine oxidase-B inhibitor, may influence cancer cells by triggering oxidative stress and altering inflammatory signaling. Researchers observed that treatment depleted glutathione levels while increasing markers like superoxide dismutase, malondialdehyde, and caspase-3. Additionally, the drug appears to modulate TLR4 and NF-κB expression and decrease IL-6 levels, suggesting a potential mechanism that disrupts glioblastoma cell growth.
Timeline
The laboratory study was conducted over a 24-hour treatment period.
Health Landscape
This study is part of the ongoing effort to evaluate existing FDA-approved medications for potential repurposing in neuro-oncology. It marks a shift toward investigating common treatments, such as Parkinson's therapies, for their activity against aggressive brain cancer cell lines.
This research is currently limited to laboratory cell cultures and does not represent a clinical treatment option for patients. Discuss any questions about current standard-of-care glioblastoma treatments or participation in clinical trials with your oncologist.
The takeaway
While these laboratory results offer a new lead for research, they are strictly preliminary and do not change medical practice today. Patients should focus on proven treatment protocols and consult their healthcare providers for the most accurate information regarding individual care plans.
Further reading
For more on current research developments, visit our Cancer section.
Source note: This article includes information reported by Nature.
